At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 10 enrolled
Drug / intervention
PF-06650833 +1 moredrug
Likely dose
PF-06650833 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, OPEN LABEL, FIXED SEQUENCE STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-06650833 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS
In Brief
A Phase 1 clinical trial evaluating PF-06650833 and Ethinyl estradiol (EE) and levonogestrel (LN) for Healthy. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This is a Phase 1, open label, fixed sequence study of the effect of multiple dose PF-06650833 on single dose OC PK in healthy female subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartOct 2021
Primary CompletionDec 2021
TodayJul 2026
First PostedOct 1, 2021
Enrollment StartOct 8, 2021
Primary CompletionDec 16, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.8 years ago
Interventions
PF-06650833drug
400 mg by mouth (PO) Once daily (QD) for 11 days
Ethinyl estradiol (EE) and levonogestrel (LN)drug
Single dose of Oral tablet containing 30 ug EE and 150 ug of LN